Related Experiment Video
Updated: Dec 27, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
[THE ROLE OF HELICOBACTER PYLORI IN ROSACEA AND PATHOGENETIC TREATMENT]
L Beridze1, T Ebanoidze2, T Katsitadze3
11Batumi Republic Clinical Hospital, Tbilisi, Georgia.
The stomach bacterium Helicobacter pylori (H. pylori) is linked to rosacea, with 80.9% of patients infected. Eradicating H. pylori effectively treats rosacea, suggesting it
Area of Science:
- Dermatology
- Gastroenterology
- Microbiology
Background:
- Rosacea is a chronic skin condition with multifactorial causes.
- An increased incidence of rosacea has been observed in individuals with Helicobacter pylori infection.
- Helicobacter pylori is a common stomach bacterium implicated in various gastrointestinal disorders.
Purpose of the Study:
- To determine the relationship between Helicobacter pylori infection and rosacea.
- To investigate the effectiveness of H. pylori eradication therapy in treating rosacea.
- To explore H. pylori as a potential pathogenic factor in rosacea development.
Main Methods:
- Patient cohort screening for H. pylori infection.
- Correlation analysis between infection rates and rosacea severity.
- Assessment of rosacea treatment outcomes following H. pylori eradication therapy.
Main Results:
- A high prevalence of H. pylori infection was found in rosacea patients (80.9%).
- A significant correlation exists between H. pylori infection rates and the severity of rosacea.
- H. pylori eradication therapy demonstrated effectiveness in treating various forms of rosacea.
Conclusions:
- Helicobacter pylori plays a significant role in the pathogenesis of rosacea.
- H. pylori eradication should be considered as a therapeutic strategy for rosacea.
- Further research into the pathophysiological aspects of H. pylori in rosacea is warranted.
More Related Videos
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

